Lumos Pharma, Inc.
LUMO · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $32 | $18 | $23 | $26 |
| - Cash | $14 | $17 | $23 | $35 |
| + Debt | $0 | $6 | $7 | $7 |
| Enterprise Value | $19 | $8 | $6 | -$3 |
| Revenue | $1 | $0 | $0 | $1 |
| % Growth | 48.8% | 195.8% | -80% | – |
| Gross Profit | $1 | $0 | $0 | $1 |
| % Margin | 100% | 99.6% | 98.8% | 97.8% |
| EBITDA | -$8 | -$8 | -$11 | -$10 |
| % Margin | -1,052.3% | -1,602.7% | -6,581.8% | -1,209% |
| Net Income | -$7 | -$8 | -$10 | -$9 |
| % Margin | -1,028.5% | -1,547.3% | -6,327.9% | -1,144.9% |
| EPS Diluted | -0.9 | -0.93 | -1.29 | -1.17 |
| % Growth | 3.2% | 27.9% | -10.3% | – |
| Operating Cash Flow | -$5 | -$6 | -$13 | -$7 |
| Capital Expenditures | $0 | $0 | $0 | -$13 |
| Free Cash Flow | -$5 | -$6 | -$13 | -$21 |